linjc16/ctgov huggingface dataset:
Training Quality in Anaesthesia and Intensive Care: Tunisian Residents Feed Back

Study Overview
=================
Brief Summary
-----------------
Opinion survey to assess the level of satisfaction and the expectations of the residents in anesthesiology and intensive care in Tunisia ( North Africa)

Detailed Description
-----------------
The first national anonymous survey to assess the theoretical and practical training quality in anesthesia and intensive care and the improvements propositions.

Official Title
-----------------
Training Quality in Anesthesia and Intensive Care : Tunisians Residents' Feed Back

Conditions
-----------------
Training Objectives Achievement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tunisian nationality Resident in anesthesiology and intensive care training period : 6 months to four year Exclusion Criteria: training done outside tunisia

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Training quality<br>Tunisian residents in anesthesiology and intensive care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the approval of theoretical and practical teaching | A standardized questionnaire assessing the theoretical and practical training was distributed to the 1th,2th,3th and 4th-year anesthesiology residents | up to four year of training | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement propositions | residents can chose from different propositions and give other propositions if not listed in the questionnaire | up to 4th year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anesthesiology and intensive care, quality, training
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

Study Overview
=================
Brief Summary
-----------------
Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction

Official Title
-----------------
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

Conditions
-----------------
Acute Heart Failure, Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Epadel, Eicosapentaenoic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sinus rhythm patients with acute heart failure or acute myocardial infarction Exclusion Criteria: pregnancy,allergy to epadel

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detection of atrial fibrillation on ECG monitoring |  | anytime during hospitalization |
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.

Detailed Description
-----------------
Patients are randomized to receive either ribavirin or a placebo for 7 days. At the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.

Official Title
-----------------
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

Conditions
-----------------
Hantavirus Pulmonary Syndrome

Intervention / Treatment
-----------------
* Drug: Ribavirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: You may be eligible for this study if you: Are 12 years of age or older. Are not pregnant. Agree to practice sexual abstinence or use accepted barrier methods of birth control/contraception. Are not breast-feeding. Have a positive blood test for hantavirus. Have symptoms suggestive of hantavirus illness. Exclusion Criteria: You will not be eligible for this study if you: Have severe low blood count (anemia). Have a diagnosis of other respiratory viruses (influenza, RSV, etc.). Have group A Streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia. Are HIV positive. Have cancer. Have had any period of irregular heartbeat. Have had chemotherapy or other drugs that suppress the immune system within 30 days. Have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.) Have taken by mouth or injection corticosteroids equivalent to approximately 0.5 mg/kg prednisone. Have taken any experimental drug within 30 days prior to enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ribavirin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

Study Overview
=================
Brief Summary
-----------------
The occurance and clinical course of human papillomavirus (HPV)-induced lesions is largely determined by the nature of the cellular immune defense generated. Even tough both genital warts and vulvar intraepithelial neoplasia (VIN) are HPV-associated genital lesions they differ in their risk of malignant progression. Imiquimod (IMQ) is a topically applied Toll-like receptor (TLR) 7 agonist that has been approved for the treatment of superficial (pre-) carcinomas of the skin (basal cell carcinomas, actinic keratosis) and HPV-associated lesions (genital warts). It acts by activation of the immune system exerting anti-tumor and anti-viral properties. The aim of the study is to evaluate the mechanisms of IMQ treatment and to analyze the differences in HPV-affected and non affected tissue at cellular and molecular level as determined by immunofluorescence stainings and real time PCR, respectively.

Official Title
-----------------
An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts

Conditions
-----------------
HPV

Intervention / Treatment
-----------------
* Drug: Imiquimod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patients with histologically proven Vulvar Intraepithelial Neoplasia 2/3 and/or anogenital Condyloma acuminata Age 18-50 Informed consent Exclusion Criteria: Malignancy Pregnancy Therapeutic Immunosupression Severe systemic dermatologic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imiquimod|Local Imiquimod three times weekly for 16 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of Cellular and Molecular Mechanisms of Imiquimod tretament and differences in HPV afeected and non affected tissue at cellular and molecular level |  | 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of histological and clinical response to therapy after 16 weeks of IMQ therapy |  | 16 weeks |
Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that spraying peppermint oil containing L-menthol onto the colonic mucosa during colonoscopy will relax smooth muscle allowing better colonic visualization.

Official Title
-----------------
Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility

Conditions
-----------------
Enhancement of the ADR During Colonoscopy

Intervention / Treatment
-----------------
* Other: Peppermint Oil
* Other: Distilled water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Screening colonoscopy Age 50 years and older Able to give consent Exclusion Criteria: No consent obtained or adult lacking capacity to consent Do not reach cecum on colonoscopy Renal impairment (defined as CrCl <30 ml/min) Allergy to study peppermint oil solution History of colon resection Inflammatory bowel disease Known colorectal neoplasia Non-correctable coagulopathy Pregnancy or lactating Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Distilled water spray as a placebo during Colonoscopy | Other: Distilled water<br>* Distilled water spray as a placebo during Colonoscopy<br>|
| Experimental: Peppermint Oil<br>Peppermint Oil spray during Colonoscopy | Other: Peppermint Oil<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of Adenoma Detection Rate during Colonoscopy Procedure |  | 2 hours |
Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus

Study Overview
=================
Brief Summary
-----------------
Background: Corneal cross linking is a procedure that induces collagen cross linking of the corneal stroma due to release of reactive oxygen radicals upon activation of topically applied riboflavine A by UVA exposure. This procedure might be capable of reducing keratocouns progression. Purpose: Although there are no randomised controlled trials on the effectiveness of corneal cross linking for the treatment of keratoconus it gains more and more importance in the general clinical setting. Therefore, the investigators started such randomised, placebo controlled, double blinded, multicenter trial to find out if this treatment is as effective as it promises to be. Methods: Randomised, placebo controlled, double blinded, multicenter trial.

Official Title
-----------------
Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus

Conditions
-----------------
Keratoconus

Intervention / Treatment
-----------------
* Procedure: Riboflavin/UVA crosslinking
* Procedure: Sham treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Only early Keratoconus (Contact lens fitting) Progression of Ametropia. Corneal thickness > 450µm Exclusion Criteria: Further ophthalmic diseases History of ocular surgery Pregnancy, brest feeding Allergy against Riboflavin End stage Keratoconus

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Procedure: Riboflavin/UVA crosslinking<br>* Removal of epithelium. Riboflavin eye drops. UVA exposure.<br>|
| Sham Comparator: 2<br> | Procedure: Sham treatment<br>* Fluorescein eye drops. Exposure with blue light<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Keratoconus progression |  | 3 years | 
| Endothelial cell loss |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keratoconus, Cross linking, Riboflavin
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Study Overview
=================
Brief Summary
-----------------
This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic agent. After a 2 week washout from their previous antidiabetic therapy, patients will receive GK Activator (2) orally, twice a day for 12 weeks, at increasing doses of 25mg bid to 200mg bid; doses will be titrated to achieve a target fasting glucose level (FPG) of <100mg/dL. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Official Title
-----------------
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.

Conditions
-----------------
Diabetes Mellitus Type 2

Intervention / Treatment
-----------------
* Drug: GK Activator (2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients, 18-75 years of age; type 2 diabetes mellitus treated with one oral antihyperglycemic agent for >=3 months prior to screening. Exclusion Criteria: type 1 diabetes mellitus; treatment with insulin, PPAR agonists or systemic corticosteroids during the 3 months prior to screening; women who are pregnant, breast-feeding or not using adequate contraceptive methods.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: GK Activator (2)<br>* 25-200mg po bid for 20 weeks<br>|
| Experimental: 2<br> | Drug: GK Activator (2)<br>* 25-200mg po bid for 20 weeks<br>|
| Experimental: 3<br> | Drug: GK Activator (2)<br>* 25-200mg po bid for 20 weeks<br>|
| Experimental: 4<br> | Drug: GK Activator (2)<br>* 25-200mg po bid for 20 weeks<br>|
| Experimental: 5<br> | Drug: GK Activator (2)<br>* 25-200mg po bid for 20 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients at each dose who achieve FPG <100mg/dL. |  | Throughout study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change in HbA1c and FPG from baseline to endpoint; absolute/relative changes in lipid profile. |  | At intervals throughout study | 
| AEs, laboratory parameters. |  | Throughout study |
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography

Study Overview
=================
Brief Summary
-----------------
Clinical evaluation of noninvasive OCT Angiography using a Zeiss OCT Prototype to replace fluorescein angiography.

Detailed Description
-----------------
Fluorescein angiography (FA) is the standard and generally accepted method to identify vascular features in the retina, detecting capillary dropout and neovessel growth. Its value is undeniable and is a routine ophthalmological examination. However, it requires intravenous injection of fluorescein, which can cause nausea, vomiting and, rarely, anaphylaxis and death. New OCT angiography methods can detect, noninvasively red blood cells flow and, therefore, identify well the retinal vasculature. It is crucial and of major interest to evaluate the clinical utility of this new methodology comparing this information with the one obtained from fluorescein angiography.

Official Title
-----------------
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography

Conditions
-----------------
Diabetic Retinopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with clinical indication for fluorescein angiography in their clinical practice Exclusion Criteria: Subjects with a pacemaker of similarly critical electronic device Subjects with severe ocular media opacities Subjects with corneal abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities). |  | Single Visit |
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.

Detailed Description
-----------------
Same as above.

Official Title
-----------------
A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: Clobetasol Propionate 0.05% Spray
* Drug: Clobetasol Propionate 0.05% Foam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved Exclusion Criteria: Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam Subjects whose psoriasis involves the scalp, face or groin Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>clobetasol propionate (Clobex®) spray | Drug: Clobetasol Propionate 0.05% Spray<br>* Apply to affected areas twice daily<br>* Other names: Clobex® Spray;|
| Active Comparator: 2<br>clobetasol propionate (Olux®) foam | Drug: Clobetasol Propionate 0.05% Foam<br>* Apply to affected areas twice daily<br>* Other names: Olux® Foam;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy - Body Surface Area, Investigator Global Severity |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety - Tolerability assessments, adverse events |  | 6 weeks |